UNC Chapel Hill
Welcome,         Profile    Billing    Logout  
 143 Trials 
290 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Le, Linda Van
NRG-GY019, NCT04095364: Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recruiting
3
450
Europe, Canada, US, RoW
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Imaging Technique, Diagnostic Imaging Technique, Image Type, Imaging, Imaging (procedure), imaging procedure, Imaging Procedures, imaging type, IMAGING_METHOD, imaging_type, Medical Imaging, Type of imaging, Letrozole, CGS 20267, Femara, Fempro, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
NRG Oncology, National Cancer Institute (NCI)
Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
02/27
02/28
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
NRG-GY026, NCT05256225: Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer

Recruiting
2/3
525
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, High-Dose-Rate Vaginal Cuff Brachytherapy, HDR-VCB, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Pertuzumab and Trastuzumab hyaluronidase, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, Phesgo, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment, Trastuzumab/Hyaluronidase-oysk, Herceptin Hylecta, Trastuzumab and Hyaluronidase, Trastuzumab and Hyaluronidase-oysk, Trastuzumab and Recombinant Human Hyaluronidase PH20, Trastuzumab and rHuPH20, Trastuzumab-Hyaluronidase-oysk
National Cancer Institute (NCI), NRG Oncology
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Uterine Corpus Carcinosarcoma
10/27
10/27
NCT05432791: Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Active, not recruiting
2/3
190
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Pazopanib, GW786034, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ, Trabectedin, Ecteinascidin, Ecteinascidin 743, ET 743, ET-743, ET743, Yondelis, Transthoracic Echocardiography, TTE
National Cancer Institute (NCI)
Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Uterine Corpus Leiomyosarcoma
03/30
03/30
NCI-2017-01672, NCT03660826: Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Active, not recruiting
2
286
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspirate, BONE MARROW, LIQUID, Human Bone Marrow Aspirate, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Capivasertib, AZD 5363, AZD-5363, AZD5363, Truqap, Cediranib, AZ-D2171, AZD 2171, AZD2171, Cediranib Maleate, AZD2171 Maleate, Recentin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281
National Cancer Institute (NCI), NRG Oncology
Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
12/24
01/26
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
125
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin
AbbVie
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
05/26
05/26
NRG-GY028, NCT05538897: Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Recruiting
1/2
96
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipatasertib, GDC 0068, GDC-0068, GDC0068, RG 7440, RG-7440, RG7440, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Megestrol Acetate, 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate, 17.alpha.-Acetoxy-6-methylpregna-4,6-diene-3,20-dione, 6-Dehydro-6-methyl-17.alpha.-acetoxyprogesterone, 6-Methyl-6-dehydro-17.alpha.-acetoxyprogesterone, BDH 1298, BDH-1298, Maygace, Megace, Megestat, Megestil, Niagestin, Ovaban, Pallace, SC 10363, SC-10363
National Cancer Institute (NCI), NRG Oncology
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma
01/27
01/27
NCT06305299: Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

Recruiting
1
27
US
iC9-CAR.B7-H3 T cells, iC9-CAR.B7-H3 T, Cyclophosphamide, Cycloblastin, Endoxan, Neosar, Procytox, Revimmune, Fludarabine, Fludara, Fludarabine Phosphate
UNC Lineberger Comprehensive Cancer Center
Ovary Neoplasm, Ovarian Cancer, Epithelial Ovarian Cancer, Recurrent
03/26
03/26
NCT04670068: Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian

Active, not recruiting
1
7
US
CAR.B7-H3, Chimeric antigen receptor T cells with B7.H3 molecular target, Fludarabine, FLUDARA, Cyclophosphamide, Cytoxan
UNC Lineberger Comprehensive Cancer Center, National Institutes of Health (NIH), National Cancer Institute (NCI)
Epithelial Ovarian Cancer
02/24
02/30
CAMPSTIM, NCT06449638: Modified Platform Trial Assessing Multiple CAMPs and SOC Vs SOC Alone in the Treatment of Hard-to-Heal DFUs

Recruiting
N/A
272
US
Standard of Care, Revita, Relese, Cogenex, Enverse
StimLabs, SerenaGroup, Inc.
Diabetic Foot Ulcer (DFU), Ulcer Foot, Diabetic Foot, Foot Ulcer
06/26
08/26
ELDERLY, NCT03065972: Hemodialysis in the Elderly (70yrs & Older)

Recruiting
N/A
270
US
Surgical fistula creation from patient's anatomy, Fistula, Surgical Graft implant, FDA approved graft (various manufacturers)
E. Peden, MD, The Methodist Hospital Research Institute
Kidney Disease, Kidney Failure, Chronic Kidney Disease
02/25
02/25
Thomas, Kathleen M
LCS, NCT06207435: Community Support Program for Lung Cancer Screening

Completed
N/A
26
US
Transportation
Abramson Cancer Center at Penn Medicine
Lung Cancer, Behavior
08/24
08/24
NCT04211155: Neural Correlates of the Shift in Social Buffering of Social Evaluative Threat

Recruiting
N/A
200
US
Questionnaires, MRI
University of Minnesota
Social Stress, Adolescent Behavior
04/24
04/24
NCT04312945: Social Buffering During Aversive Conditioning

Recruiting
N/A
200
US
Questionnaires, MRI
University of Minnesota
Social Stress, Adolescent Behavior
11/25
11/25
NCT04311996: Does Social Buffering Continue to be Effective Over the Peripubertal Period When Friends Share the Stressor Experience?

Recruiting
N/A
200
US
Questionnaires, TSST, Trier Social Stress Test
University of Minnesota
Adolescent Behavior, Social Stress
10/24
10/24
NCT05835362: Improving the Outcomes of Adolescents With ADHD Via a Pre-visit Question Prompt List/Video Intervention

Recruiting
N/A
140
US
Question prompt list, Pre-visit video, Combined question prompt list/video
University of North Carolina, Chapel Hill, National Institute of Mental Health (NIMH)
ADHD
07/25
11/25
NCT05986305: Improving the Health of Parents and Their Adolescent and Transition-age Youth With Intellectual and Developmental Disabilities

Recruiting
N/A
404
US
Go Act, Peer
University of North Carolina, Chapel Hill, Patient-Centered Outcomes Research Institute
Intellectual Disability
03/26
03/26
Shaheen, Nicholas
NCT06732388: Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

Not yet recruiting
2
64
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Endoscopic Procedure, Endoscopic Examination, Endoscopy, ES, Itraconazole, Lozanoc, Oriconazole, R 51,211, Sporanox, Placebo Administration, Questionnaire Administration, Radiofrequency Ablation, Ablation, Radiofrequency, Radiofrequency Interstitial Ablation, RFA
National Cancer Institute (NCI)
Barrett Esophagus, Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Esophageal Adenocarcinoma
01/28
01/28
NCT04939051: Obeticholic Acid for Prevention in Barrett's Esophagus

Recruiting
2
30
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Esophageal Biopsy, Biopsy of Esophagus, Esophagogastroduodenoscopy, EGD, Upper Endoscopy, Liver Ultrasonographic Elastography, Fibroscan, TE, Transient Elastography, VCTE, Vibration-Controlled Transient Elastrography, Obeticholic Acid, INT-747, Ocaliva, Placebo Administration, Questionnaire Administration
National Cancer Institute (NCI)
Barrett Esophagus, Esophageal Adenocarcinoma
09/25
09/26
NCT03243734: trūFreeze® Palliative Esophageal Cancer

Completed
N/A
49
US
trūFreeze® System spray cryotherapy
US Endoscopy Group Inc.
Esophageal Cancer
07/22
03/24
NCT04316975: Utility Of Mutational Load As A Predictor For Endoscopic Treatment Response In Barrett's Esophagus

Completed
N/A
75
US
Study Driven Procurement of Biopsies, Research Biopsies
University of North Carolina, Chapel Hill, Interpace Diagnostics Corporation
Barretts Esophagus With Dysplasia, Intramucosal Adenocarcinoma
12/23
12/23
NCT06687603: Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms

Not yet recruiting
N/A
800
US
EsoCheck, EsoGuard
Case Comprehensive Cancer Center
Barrett Esophagus, Gastroesophageal Reflux, Esophageal Adenocarcinoma
09/28
09/29
BEECAB, NCT02427269: University of North Carolina (UNC) Barrett's Esophagus and Esophageal Cancer Biorepository

Enrolling by invitation
N/A
1000
US
Specimen Collection
University of North Carolina, Chapel Hill
Barrett's Esophagus, Esophageal Cancer, Intramucosal Adenocarcinoma
05/25
05/25
ReBET, NCT03554356: Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE)

Recruiting
N/A
70
US
CryoBalloon Focal Ablation System
University of North Carolina, Chapel Hill, PENTAX of America, Inc., Johns Hopkins University
Barrett Esophagus, Intestinal Metaplasia, Esophageal Dysplasia
12/26
12/26
SWAT-BE, NCT05530343: Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance

Recruiting
N/A
2298
US
Seattle protocol, WATS3D brushings
University of Colorado, Denver
Barrett Esophagus, Barretts Esophagus With Dysplasia, Esophageal Adenocarcinoma
03/26
03/26
SURVENT, NCT05753748: Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia

Recruiting
N/A
680
US
Endoscopic Eradication Therapy
University of Colorado, Denver, Baylor University, University of North Carolina, Medical University of South Carolina, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Barretts Esophagus With Dysplasia, Barrett Esophagus, Esophageal Adenocarcinoma
02/28
02/28
FBE, NCT00288119: Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

Recruiting
N/A
2000
US
Balloon Capsule Device, Esophageal Sampling Device BESD-001, Endoscopy, EGD
Case Western Reserve University, University Hospitals Cleveland Medical Center, Washington University School of Medicine, Fred Hutchinson Cancer Center, University of Washington, Mercy Medical Center, Johns Hopkins University, Mayo Clinic, University of North Carolina, Chapel Hill, The Cleveland Clinic, University of Pennsylvania, Columbia University, VA Puget Sound Health Care System
Barrett's Esophagus, Esophageal Neoplasm
07/28
07/28
Samuel-Hodge, Carmen
NCT05067816: Med-South Lifestyle Program Implementation Study

Completed
N/A
368
US
Med-South Lifestyle Program, Med-South Program
University of North Carolina, Chapel Hill, Centers for Disease Control and Prevention
Healthy Lifestyle
09/23
02/24
DELISH, NCT04302727: Delicious Eating for Life in Southern Homes

Completed
N/A
360
US
Med-South Weight Loss Intervention, Delicious Eating for Life in Southern Homes (DELISH) Weight Loss Program, WW, Weight Watchers
University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI)
Weight Loss, Diet, Healthy, Cardiovascular Risk Factor
05/24
05/24
FAM WEL B-ing, NCT06724406: FAMily-centered WEight Loss for Black Adults

Not yet recruiting
N/A
256
US
Family Skills Training Session Quantity: 5, Family Skills Training Session Mode: In-person, Family Skills Training Content: Communication, Family Skills Training Content: Cohesion, Family Skills Training Session Quantity: 10, Family Skills Training Session Mode: Online, Family Skills Training Content: No Communication, Family Skills Training Content: No Cohesion
University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI)
Obesity and Overweight, Diabetes Mellitus, Weight Loss, Behavior Change
07/28
07/28
Farber, Mark O
stAAAble, NCT06001918: Nectero EAST System Clinical Study

Recruiting
2/3
400
US
Nectero EAST System
Nectero Medical, Inc.
Abdominal Aortic Aneurysm
03/27
12/29
NCT02396199: Zenith® p-Branch® Endovascular Graft Pivotal Study

Active, not recruiting
N/A
80
US
Zenith® p-Branch® in combination with the Atrium iCAST™ covered stents, Endovascular graft, Endovascular stent, Stent-graft, Fenestrated graft
Cook Research Incorporated
Aortic Aneurysm Abdominal
04/21
04/25
NCT05004051: ViTAA Registry Pre- and Post-Operative Monitoring for Endovascular Aortic Aneurysm Repair and Serial Monitoring for AAA

Recruiting
N/A
200
Canada, US
ViTAA Analysis
ViTAA Medical Solutions
Abdominal Aortic Aneurysms
12/26
12/26
TRIOMPHE, NCT04471909: NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness

Recruiting
N/A
110
US, RoW
NEXUS Aortic Stent Graft System
Endospan Ltd.
Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
11/24
10/29
TAMBE, NCT05442489: Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of the Thoracoabdominal and Pararenal Aortic Aneurysms

Approved for marketing
N/A
US
GORE Excluder Thoracoabdominal Branch Endoprosthesis, TAMBE
W.L.Gore & Associates
Thoracoabdominal Aneurysm
 
 
TAMBE, NCT03728985: Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms

Active, not recruiting
N/A
102
Europe, US
GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, TAMBE
W.L.Gore & Associates
Thoracoabdominal Aortic Aneurysm
01/23
09/26
IMPROVE-AD, NCT06087029: IMPRoving Outcomes in Vascular DisEase- Aortic Dissection

Recruiting
N/A
1100
US
TEVAR, Guideline directed medical therapy and surveillance of dissection
Duke University, The University of Texas Health Science Center, Houston, State University of New York - Downstate Medical Center, Oregon Health and Science University, National Heart, Lung, and Blood Institute (NHLBI)
Type B Aortic Dissection
06/30
06/30
NCT01654133: Evaluation of Visceral Function Following Endovascular Aortic Aneurysm Repair Using Branched Stent- Grafts

Enrolling by invitation
N/A
645
US
Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using branched stent graft, Endovascular repair of thoracoabdominal aortic aneurysm, Endovascular repair of ascending/arch aortic aneurysm using branched stent graft, Endovascular repair of ascending/ arch aortic aneurysm
University of North Carolina, Chapel Hill, UNC Hospitals, Cook Group Incorporated
Aortic Aneurysm, Abdominal, Ascending Aorta Aneurysm, Aortic Arch Aneurysm
08/30
08/30
Jones, Deborah
CHIEF PD, NCT04226248: CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)

Active, not recruiting
3
600
Europe
Rivastigmine Transdermal System, Placebo Transdermal System
University of Bristol, Royal United Hospitals Bath NHS Foundation Trust
Parkinson Disease
05/24
02/25
Burks, Wesley
Peanut OIT, NCT00598039: Peanut Oral Immunotherapy

Active, not recruiting
N/A
40
US
Peanut flour
University of North Carolina, Chapel Hill, University of Arkansas
Food Hypersensitivity
07/14
07/14
Dichter, Gabriel S
PEEPS, NCT05282277: Examining the Effects of Estradiol on Neural and Molecular Response to Reward

Recruiting
4
103
US
Transdermal Estradiol, Climara, Micronized Progesterone, Prometrium, Matching Placebo Patch, Placebo, Raclopride C11, [C11]Raclopride
University of North Carolina, Chapel Hill, National Institute of Mental Health (NIMH)
Depression, Psychosis, Anhedonia
12/26
12/26
NCT04036136: Development of a Novel Transdiagnostic Intervention for Anhedonia - R33 Phase

Completed
N/A
116
US
Behavioral Activation, Mindfulness Treatment
University of North Carolina, Chapel Hill, Duke University, National Institute of Mental Health (NIMH)
Anhedonia
07/23
07/23
Dellon, Evan S
DESTRICT, NCT06352073: Dupilumab for Eosinophilic Esophagitis With Severe Strictures

Recruiting
4
30
US
Dupilumab, Dupilumab Pre-filled Syringe, Dupixent
University of North Carolina, Chapel Hill, Regeneron Pharmaceuticals, Sanofi
Eosinophilic Esophagitis, EoE
11/25
04/26
FLUTE-3, NCT05634746: 24-Week Induction Study of APT-1011 in Adult Subjects with Eosinophilic Esophagitis (EoE) (FLUTE 3)

Completed
3
218
Canada, US
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Ellodi Pharmaceuticals, LP
Eosinophilic Esophagitis
08/24
08/24
DEGS, NCT03678545: Dupilumab in Eosinophilic Gastritis

Active, not recruiting
2
41
US
Dupilumab (blinded), Placebo (blinded), Dupilumab (open-label)
Children's Hospital Medical Center, Cincinnati, Regeneron Pharmaceuticals, National Institutes of Health (NIH)
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
03/24
11/24
iDIET, NCT05543512: The Immune Directed Individualized Elimination Therapy () Study

Enrolling by invitation
N/A
100
US
Algorithm to diagnose food allergens, Sham diet
University of North Carolina, Chapel Hill, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Mayo Clinic
Eosinophilic Esophagitis, EoE
01/25
01/25
NCT01988285: Risk Factors and Biomarkers for Diagnosis and Treatment of EoE

Active, not recruiting
N/A
800
US
Specimen Collection, Questionnaires
University of North Carolina, Chapel Hill, National Institutes of Health (NIH)
Eosinophilic Esophagitis
08/25
08/25
NCT02523118: OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages

Recruiting
N/A
1350
US
Children's Hospital Medical Center, Cincinnati, National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), ORDR, National Center for Advancing Translational Sciences (NCATS)
Eosinophilic Gastrointestinal Disorders (EGIDs), Eosinophilic Esophagitis, Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Colitis
12/50
01/51
Kappelman, Michael
PROMOTE IBD, NCT06424769: Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management

Recruiting
N/A
900
US
Enhanced Digital Care, Education
University of North Carolina, Chapel Hill, University of Pennsylvania, Centers for Disease Control and Prevention
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Colitis
09/28
09/28
Bulik, Cynthia
EDGI, NCT04378101: Eating Disorders Genetics Initiative

Completed
N/A
17991
US, RoW
Eating disorder diagnosis group
University of North Carolina, Chapel Hill, National Institute of Mental Health (NIMH), University of Otago, University of Aarhus, QIMR Berghofer Medical Research Institute
Anorexia Nervosa, Bulimia Nervosa, Binge-Eating Disorder
05/23
05/23
ARFID-GEN, NCT05605067: Genetic Architecture of Avoidant/Restrictive Food Intake Disorder

Completed
N/A
5076
US
University of North Carolina, Chapel Hill, National Institute of Mental Health (NIMH), Psychiatric Center Ballerup
ARFID, Eating Disorders, Eating Disorders in Children, Eating, Picky
08/24
08/24
EDGI2, NCT06594913: Eating Disorders Genetics Initiative 2

Recruiting
N/A
20000
Europe, US, RoW
Eating disorder diagnosis group
University of North Carolina, Chapel Hill, Queensland Institute of Medical Research, Karolinska Institutet, National Institute of Mental Health (NIMH), University of Otago, University of Aarhus, Yale University, Comenzar de Nuevo A.C., University of Sydney
Anorexia Nervosa, Bulimia Nervosa, Binge-Eating Disorder, Avoidant Restrictive Food Intake Disorder
08/27
08/27
Girdler, Susan
NCT05388656: Estrogen Variability and Irritability During the Menopause Transition

Recruiting
4
50
US
Estradiol Patch, 0.1 mg/24 Hours Weekly Transdermal Film, Extended Release, Placebo, Progesterone 200 mg, Prometrium
University of North Carolina, Chapel Hill, National Institute of Mental Health (NIMH)
Menopause, Irritable Mood
12/24
12/24
BRX-PPD, NCT05543746: Dynamic Neural Mechanisms of Brexanolone-induced Antidepressant Effects in Postpartum Depression

Completed
N/A
10
US
Brexanolone, Zulresso
University of North Carolina, Chapel Hill, Baszucki Brain Research Fund, Sage Therapeutics
Postpartum Depression
11/23
11/23
Wood, William J
NCT04223765: Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Recruiting
1
20
US
CAR.k.28, Kappa Chimeric Antigen Receptor and CD28 Endodomain, Fludarabine, FLUDARA, Cyclophosphamide, Cytoxan, Bendamustine, Bendeka, Treanda
UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI)
Mantle Cell Lymphoma, Follicular Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma
03/28
03/43
COSMIC, NCT05831787: COVID19 OutcomeS in Myeloma and the Impact of VaCcines

Active, not recruiting
N/A
200
US
Patient Reported Outcomes
ASH Research Collaborative, ModernaTX, Inc.
Multiple Myeloma
12/24
01/25
NCT06618274: Effectiveness of Central Oncology Navigation and the Use of an ORN

Not yet recruiting
N/A
686
US
Intervention of oncology research navigator embedded in central oncology navigation, oncology research navigator (ORN, Central oncology navigation (SOC)
UNC Lineberger Comprehensive Cancer Center
Cancer, Malignant Tumor
01/27
07/31
SCOPE-L, NCT05237258: Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Recruiting
N/A
2300
US
Specialty Palliative Care, Primary Palliative Care
Massachusetts General Hospital, Patient-Centered Outcomes Research Institute
Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
04/28
04/29
HealthScore, NCT04923997: The Health Coaching Program

Recruiting
N/A
500
US
Health Coaching
UNC Lineberger Comprehensive Cancer Center
Cancer, Survivorship, Quality of Life, Health Behavior
04/30
04/30
Ward, Dianne S
NCT03938103: Evaluation of an Enhanced Delivery Model for Go NAPSACC

Completed
N/A
364
US
Enhanced Go NAPSACC, Basic Go NAPSACC
University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI), University of Kentucky, Child Care Aware of Kentucky
Obesity
10/22
12/22
NCT05887401: Physical Activity and Healthy Eating Among Young Adult Cancer Survivors

Recruiting
N/A
100
US
Core, Simplified Nutrition Monitoring (Green), Behavioral: Simplified Nutrition Monitoring (Red), Nutrition Goals (Yes), Nutrition Goals (No), Supportive Text Messages (Yes), Supportive Text Messages (No), Lesson Delivery (Once), Lesson Delivery (Weekly)
UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI)
Physical Activity, Neoplasms, Cancer
03/25
03/25
Hightow-Weidman, Lisa
NCT03132415: Get Connected Efficacy Trial

Completed
N/A
285
US
Get Connected, HIV Test Locator
University of Pennsylvania, University of North Carolina, University of Michigan, University of Minnesota, Emory University, Children's Hospital of Philadelphia, Baylor College of Medicine
HIV Infections
12/21
06/22
NCT05490329: Addressing Vaccine Hesitancy and Increasing COVID-19 Vaccine Uptake Among African American Young Adults in the South

Completed
N/A
360
US
Tough Talks COVID
Florida State University, National Institute on Minority Health and Health Disparities (NIMHD)
COVID-19, Vaccine Uptake
12/23
12/23
NCT03678181: Increasing Engagement and Improving HIV Outcomes Via HealthMPowerment

Completed
N/A
750
US
Information Resources, Social Support, HIV Testing
University of Pennsylvania, University of North Carolina, Duke University
HIV Infections, Sexually Transmitted Diseases, Stigma, Social
10/23
10/23
Rossi, Joseph
PEERLESS, NCT05111613: The Study

Completed
N/A
692
Europe, US
Catheter-Directed Thrombolysis, FlowTriever System
Inari Medical
Pulmonary Embolism, Pulmonary Thrombo-embolism
03/24
04/24
ECLIPSE, NCT03108456: Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The Trial

Active, not recruiting
N/A
2005
US
Orbital Atherectomy, Balloon
Abbott Medical Devices, Cardiovascular Research Foundation, New York
Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
06/24
06/25
CorCinch-HF, NCT04331769: Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF): the CORCINCH-HF Study

Recruiting
N/A
400
Europe, US, RoW
AccuCinch Ventricular Restoration System, Guideline-Directed Medical Therapy
Ancora Heart, Inc.
Heart Failure with Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
12/26
12/30
Massarotti, Elena M
RESET-SLE, NCT06121297: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Recruiting
1/2
12
Europe, US
CABA-201
Cabaletta Bio
Systemic Lupus Erythematosus, Lupus Nephritis
12/27
12/27
Foster, Matthew
NCT03016377: Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

Recruiting
1/2
54
US
iC9-CAR19 cells, CAR.CD19 T cells, Rimiducid, AP1903, Cyclophosphamide, Neosar, Fludarabine, Fludara
UNC Lineberger Comprehensive Cancer Center, Bellicum Pharmaceuticals, The Leukemia and Lymphoma Society
Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders
04/26
04/41
NCT03594162: Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch

No Longer Available
N/A
US
iC9-CAR19 cells, CAR.CD19 T cells, AP1903, Rimiducid, Cyclophosphamide, Neosar, Fludarabine, Fludara
UNC Lineberger Comprehensive Cancer Center, Bellicum Pharmaceuticals
Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders
 
 
Blatt, Julie
EPIK-P2, NCT04589650 / 2020-000561-16: Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

Recruiting
2
205
Europe, Canada, US, RoW
Alpelisib, Placebo
Novartis Pharmaceuticals
PIK3CA-related Overgrowth Spectrum (PROS)
03/24
04/31
Anders, Carey K
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
BRIDGET, NCT05323955: Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients with ADvanced Human Epidermal Growth Factor Receptor 2+ BrEast Cancer with the Addition of Tucatinib

Recruiting
2
48
US
Trastuzumab, Herceptin, Trastuzumab Emtansine (T-DM1), Pertuzumab, Perjeta, Tucatinib, Tukysa
Carey Anders, M.D., Pfizer
Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
10/26
10/27
NCT03994796: Genetic Testing in Guiding Treatment for Patients with Brain Metastases

Recruiting
2
186
US
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
10/26
06/28
SOLARA, NCT04711824: Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases

Recruiting
1/2
41
US
Olaparib, Lynparza, Stereotactic Radiosurgery, SRS, Durvalumab, Imfinzi, Physicians Choice systemic chemotherapy, Paclitaxel, Nab-paclitaxel, Eribulin, Carboplatin, Cisplatin, Capecitabine, Gemcitabine
Colette Shen, AstraZeneca, University of North Carolina, Chapel Hill
Breast Cancer, Brain Metastases, Adult
11/25
11/26
ELU-FRα-1, NCT05001282: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Terminated
1/2
79
US
ELU001, FA-CDC
Elucida Oncology
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer
06/24
06/24
Lilly-I3Y-US-I026, NCT04791384: Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

Recruiting
1/2
44
US
Abemaciclib, Verzenio, Elacestrant
Criterium, Inc.
Breast Cancer
12/24
01/25
INX-315-01, NCT05735080: Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Recruiting
1/2
90
US, RoW
INX-315, Fulvestrant, faslodex
Incyclix Bio
Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Ovarian Cancer, CCNE1 Amplification, Solid Tumor, Advanced Cancer, Metastatic Cancer
12/25
06/26
NCT05593094: A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors

Recruiting
1
210
Europe, US, RoW
ZN-A-1041 50mg BID, ZN-A-1041 Enteric Capsules, ZN-A-1041 100mg BID, ZN-A-1041 200mg BID, ZN-A-1041 400mg BID, ZN-A-1041 600mg BID, ZN-A-1041 800mg BID, ZN-A-1041 1000mg BID, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1b, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1b, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1b, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase1c, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase1c, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase1c
Suzhou Zanrong Pharma Limited
Advanced Solid Tumors, HER2-positive Breast Cancer
10/25
10/26
Weiss, Jared
WAVE, NCT04078152 / 2019-001402-20: Durvalumab Long-Term Safety and Efficacy Study

Completed
4
163
Europe, Canada, Japan, US, RoW
Durvalumab, MEDI4736
AstraZeneca, Iqvia Pty Ltd, Parexel, Medidata Solutions, CISCRP
Solid Tumor
10/22
10/24
NCT01612351: Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

Active, not recruiting
2
40
US
Carboplatin, Paraplatin, Paclitaxel, Taxol, Lapatinib, Tykerb, Cisplatin, Platinol, Ipsilateral Radiation, Radiation therapy, Bilateral Radiation, Transoral Surgery, Surgery
UNC Lineberger Comprehensive Cancer Center, GlaxoSmithKline
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
11/16
11/31
NCT03174275: Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

Active, not recruiting
2
39
US
Durvalumab, MEDI4736, Carboplatin, Paraplatin, Nab-paclitaxel, Abraxane, Cisplatin, Surgical resection, IMRT, Intensity-modulated radiation therapy
UNC Lineberger Comprehensive Cancer Center, AstraZeneca, Celgene
Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer, Larynx Cancer, Lip Cancer, Esophageal Cancer
02/22
02/27
NCT02609503: Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin

Checkmark For stage III-IV head and neck squamous cell carcinoma
Jun 2020 - Jun 2020: For stage III-IV head and neck squamous cell carcinoma
Completed
2
29
US
Pembrolizumab, Keytruda, Intensity Modulated Radiation Therapy, IMRT
UNC Lineberger Comprehensive Cancer Center, Merck Sharp & Dohme LLC
Head and Neck Cancer
12/19
11/23
VERSATILE-002, NCT04260126: Study of PDS0101 and Pembrolizumab Combination I/O in Subjects with HPV16 + Recurrent And/or Metastatic HNSCC

Checkmark Data from VERSATILE-002 clinical trial in combination with PDS0101 for metastatic head and neck cancer at MHNCS 2022
Feb 2022 - Feb 2022: Data from VERSATILE-002 clinical trial in combination with PDS0101 for metastatic head and neck cancer at MHNCS 2022
Active, not recruiting
2
95
Europe, US
Pembrolizumab (KEYTRUDA®) and PDS0101
PDS Biotechnology Corp., Merck Sharp & Dohme LLC
Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck
06/25
06/25
NCT05578326: Study of Trilaciclib and Lurbinectidin

Recruiting
2
30
US
Trilaciclib, Lurbinectedin
UNC Lineberger Comprehensive Cancer Center, G1 Therapeutics, Inc.
Lung Cancer, Small-cell Lung Cancer
12/25
12/27
LIBRETTO-001, NCT03157128 / 2017-000800-59: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Hourglass Apr 2022 - Dec 2022 : Approval in China for RET+NSCLC, medullary thyroid cancer and thyroid cancer
Hourglass Jan 2022 - Dec 2022 : Submission for lung cancer
Checkmark From LIBRETTO-001 trial in RET fusion-positive NSCLC
Aug 2020 - Aug 2020: From LIBRETTO-001 trial in RET fusion-positive NSCLC
Checkmark Granted for advanced RET fusion+ve 2L thyroid cancer [LIBRETTO-001]
More
Active, not recruiting
1/2
856
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Loxo Oncology, Inc., Eli Lilly and Company
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
02/25
02/26
NCT03917381 / 2018-003402-63: GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Active, not recruiting
1/2
429
Europe, US, RoW
Acasunlimab, GEN1046, DuoBody®-PD-L1x4-1BB, Acasunlimab in combination with docetaxel (in a single expansion cohort), Acasunlimab in combination with pembrolizumab (in a separate expansion cohort), Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
Genmab, BioNTech SE
Solid Tumors, Non-small Cell Lung Cancer, Urothelial Carcinoma, Endometrial Carcinoma, Triple Negative Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, Cervical Cancer
02/26
02/26
NCT05375994: Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

Active, not recruiting
1/2
85
US
avutometinib (VS-6766) and adagrasib, KRAS G12C Inhibitor, adagrasib, KRAZATI®
Verastem, Inc., Mirati Therapeutics Inc.
Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung, Malignant Neoplastic Disease
12/24
01/25
SKYBRIDGE, NCT05652686: A Study of Peluntamig (PT217) in Patients with Neuroendocrine Carcinomas Expressing DLL3 (the Study)

Recruiting
1/2
203
US
Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel., Atezolizumab
Phanes Therapeutics, Hoffmann-La Roche
Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Neuroendocrine Carcinomas (NEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
12/27
08/28
NCT06096038: Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

Recruiting
1/2
33
US
Cyclophosphamide, Cycloblastin, Cytoxan, Endoxan, Neosar, Procytox, Revimmune, Fludarabine, Fludara, Fludarabine Phosphate, Cell Therapy
UNC Lineberger Comprehensive Cancer Center, Bellicum Pharmaceuticals, University Cancer Research Fund at Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI)
Head and Neck Cancer, Relapse, Recurrent, Refractory Cancer
09/26
09/28
PANDA-VAC, NCT04266730: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab

Not yet recruiting
1
6
US
PANDA-VAC, Personalized and adaptive neoantigen dose-adjusted vaccine, Pembrolizumab
UNC Lineberger Comprehensive Cancer Center
Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
06/26
06/33
NCT05911308: Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Recruiting
1
24
US
Durvalumab, Imfinzi, Carboplatin, Paraplatin, Abequolixron, RGX 104, RGX-104, RGX104, SB-742881, Abraxane, Paclitaxel albumin-bound, Nab-paclitaxel, Pemetrexed, Alimta
UNC Lineberger Comprehensive Cancer Center, AstraZeneca, Rgenix, Inc.
Non-Small Cell Lung Cancer
12/25
12/26
NCT05620342: Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

Recruiting
1
24
US
iC9.GD2.CAR.IL-15 T Infusion
UNC Lineberger Comprehensive Cancer Center, Bellicum Pharmaceuticals, United States Department of Defense
Lung Cancer, Small Cell Lung Carcinoma, Non Small Cell Lung Cancer
02/25
02/27
NCT05973487: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

Recruiting
1
100
US
TSC-204-A0201, TSC-204-C0702, TSC-200-A0201, TSC-204-A0201 + TSC-204-C0702, TSC-204-A0201 + TSC-200-A0201, TSC-204-C0702 + TSC-200-A0201, TSC-204-A0201 + TSC-203-A0201, TSC-204-C0702 + TSC-203-A0201, TSC-200-A0201 + TSC-203-A0201, TSC-203-A0201, TSC-204-A0101, TSC-201-B0702, TSC-204-A0201 + TSC-204-A0101, TSC-204-A0201 + TSC-201-B0702, TSC-204-C0702 + TSC-204-A0101, TSC-204-C0702 + TSC-201-B0702, TSC-200-A0201 + TSC-204-A0101, TSC-200-A0201 + TSC-201-B0702, TSC-203-A0201 + TSC-204-A0101, TSC-203-A0201 + TSC-201-B0702
TScan Therapeutics, Inc.
Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
12/26
12/26
NCT05812027: A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

Recruiting
N/A
650
US
Tumor and HLA Profiling
TScan Therapeutics, Inc.
Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, Melanoma, Ovarian Cancer, HPV16 Related Cancers
01/26
01/27
Lewek, Michael D
NCT05625789: How to Get Started: Identifying the Critical Ingredients to Improve Gait Initiation in Parkinson Disease

Completed
N/A
10
US
Postural control (weight shift) training, Steady state gait training
University of North Carolina, Chapel Hill, LSVT Global
Parkinson Disease
08/24
08/24
NCT05447884: Improving Balance and Energetics of Walking Using a Hip Exoskeleton

Recruiting
N/A
100
US
A zero impedance mode, controlling a wearable bilateral hip exoskeleton, A personalized optimal assistance mode, controlling a wearable bilateral hip exoskeleton, A free walking mode, without wearing a wearable bilateral hip exoskeleton
North Carolina State University, University of North Carolina, Chapel Hill
Stroke
12/24
12/25
NCT05864157: Targeted Motor Learning to Improve Gait for Individuals With Parkinson Disease

Recruiting
N/A
45
US
Gait training without rhythmic auditory cues, TRAC, dTRAC
University of North Carolina, Chapel Hill, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Parkinson Disease
05/26
05/26
Long, Jason
PLOTS, NCT04066699: Percutaneous Localization: Open-label Registry of Thoracic Surgery

Completed
N/A
70
US
Percutaneous localization of suspicious lung lesion(s) using electromagnetic navigation and tools., SPiN Thoracic Navigation System™, Veran System
Veran Medical Technologies
Lung Lesion(s) Requiring Evaluation, Pulmonary Metastasis, Pulmonary Nodule, Solitary, Peripheral Lung Lesions
01/23
02/23
McNaull, Peggy P
NCT04376762: Comparison of Fibrinogen Concentrate and Cryoprecipitate in Pediatric Cardiac Surgery Patients

Completed
4
30
US
Fibrinogen, Fibrinogen Concentrate (Human) Injection [Fibryga], Cryoprecipitate
University of Virginia, Octapharma
Pediatric HD, Bleeding
03/23
05/23
 

Download Options